Bio-Rad debuts guide to improve access to COVID-19 tests

By staff writers

March 16, 2020 -- Bio-Rad Laboratories has launched a standard for SARS-CoV-2 to help labs validate assays and speed up access to testing for COVID-19 novel coronavirus disease.

The standard contains synthetic COVID-19 RNA transcripts and human genomic DNA, allowing laboratories to test the process of a molecular assay, including extraction, amplification, and detection of the virus. These specifications also enable more laboratories to meet the growing demand of identifying those infected with the coronavirus, according to Bio-Rad.

The CLIA federal regulatory standards require clinical laboratories to establish and document their performance specifications for laboratory-developed tests to ensure accurate and precise results prior to implementation.

ASM: Reagent shortages threaten coronavirus test access
Shortages in SARS-CoV-2 polymerase chain reaction reagents are threatening access to coronavirus test kits, according to a statement released on March...
Study outlines 1st person-to-person coronavirus spread
A study published March 12 in the Lancet journal describes what is believed to be the first person-to-person transmission of the SARS-CoV-2 virus...
3 ways the U.S. went wrong with COVID-19 testing
Diagnostic testing for any new virus is crucial to its containment, but since the COVID-19 outbreak began, the U.S. has made a number of missteps that...
Study identifies risk factors for death from coronavirus
For individuals with the novel coronavirus disease, several factors were associated with an increased risk of death in a new study, published online March...
Laboratories, IVD vendors get to work on novel coronavirus
The emergence of novel viruses underscores the need for laboratories to be vigilant and for IVD vendors to constantly update test menus, writes Bruce...

Copyright © 2020

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current